ReviewJournal of clinical medicine2016
Tumor Budding: The Name is EMT. Partial EMT.
Review in Journal of clinical medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 283 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
283 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The relationship between tumor budding and survival of patients with breast cancer: A meta-analysis.Biomolecules & biomedicine · 2024Pooled it
- Tumor Budding as a Marker for Poor Prognosis and Epithelial-Mesenchymal Transition in Lung Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Clinical significance of tumor-stroma ratio in head and neck cancer: a systematic review and meta-analysis.BMC cancer · 2021Pooled it
- Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly.Frontiers in endocrinology · 2021Pooled it
- Tumor Invasive Border Index (TIBI) in colorectal cancer: linking infiltrative morphology to molecular insights.The Journal of pathology · 2026Article
- PLAU accelerates extracellular matrix remodeling through partial epithelial-mesenchymal transition in head and neck squamous cell carcinoma.Translational cancer research · 2026Article
- Tumor budding in non-small cell lung cancer: a new prognostic frontier?Updates in surgery · 2026Article
- Cellular-state control using ribozyme-scaffolded miRNA-sensing and CRISPR-mediated actuation.Cell reports methods · 2026Article
- Exploration of the mechanism by which Ubiquitin-like protein UBD promotes malignant progression of breast cancer.Medical oncology (Northwood, London, England) · 2026Article
- Tumor Budding in Gastric Carcinoma: Beyond Counting Cells at the Invasive Front-A Review of Current Evidence and Biological Perspectives.International journal of molecular sciences · 2026Review
- MDK Activates the PI3K/AKT Axis to Induce AP2A1 Expression and Epithelial-Mesenchymal Transition in Colorectal Cancer.Cancers · 2026Article
- Spatial transcriptomics reveals a molecular tumor budding signature in head and neck cancer.Genome medicine · 2026Article
- Tumor Budding in Colorectal Carcinoma-From Incidental Observation to Prognostic Marker: Lessons Learned from Colorectal Cancer Assessment.Medicina (Kaunas, Lithuania) · 2026Review
- CDX2 expression dynamics in tumor clusters: a morpho-molecular biomarker in rectal cancer pretreatment biopsies revealed by sequential immunofluorescence.Scientific reports · 2026Article
- Involvement of Membranous S100A10 Expression in the Tumor Budding of Colorectal Cancer: An Immunohistochemical Study.Journal of gastrointestinal cancer · 2026Article
- Assessing Tumour Budding in Lung Squamous Cell Carcinoma: A Comparative Analysis of Digital Whole-Slide Imaging and Light Microscopy.Pathobiology : journal of immunopathology, molecular and cellular biology · 2026Article
- Predicting survival in oral squamous cell carcinoma via integrated analysis of tumor budding and tertiary lymphoid structures.Frontiers in oncology · 2026Article
- Comprehensive analysis based on tertiary lymphoid structures and tumor budding predicts survival rates in colorectal cancer patients with synchronous liver metastases.Frontiers in immunology · 2026Article
- New Advancements in Prognostic Biomarkers for Upper Tract Urothelial Carcinoma.Current medicinal chemistry · 2026Review
- Cytoplasmic Basigin Localization is Associated with EMT, Tumor Budding, and Adverse Prognosis in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
223 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tumor budding is a histological phenomenon encountered in various cancers, whereby individual malignant cells and/or small clusters of malignant cells are seen in the tumor stroma. Postulated to be mirror epithelial-mesenchymal transition, tumor budding has been associated with poor cancer outcomes. However, the vast heterogeneity in its exact definition, methodology of assessment, and patient stratification need to be resolved before it can be routinely used as a standardized prognostic feature. Here, we discuss the heterogeneity in defining and assessing tumor budding, its clinical significance across multiple cancer types, and its prospective implementation in clinical practice. Next, we review the emerging evidence about partial, rather than complete, epithelial-mesenchymal phenotype at the tumor bud level, and its connection with tumor proliferation, quiescence, and stemness. Finally, based on recent literature, indicating a co-expression of epithelial and mesenchymal markers in many tumor buds, we posit tumor budding to be a manifestation of this hybrid epithelial/mesenchymal phenotype displaying collective cell migration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.